Neurosciences - 28/02/2024 Mesh microelectrode arrays: research with brain organoids on a new level How does the brain work? Brain organoids are derived from pluripotent stem cells and regarded as valuable model systems that can depict some aspects of neurological functioning. Dr. Peter Jones from NMI together with Dr. Thomas Rauen from the MPI for Molecular Biomedicine in Münster, has taken organoid research to a new level. His novel mesh microelectrode array (Mesh-MEA) greatly improves the growth and electrophysiological analysis of tissue.https://www.gesundheitsindustrie-bw.de/en/article/news/mesh-microelectrode-arrays-research-brain-organoids-new-level
Funding EU Joint Programme - Neurodegenerative Disease Research (JPND): Mechanisms and measurement of disease progression in the early phase of neurodegenerative diseases Funding programme, Funded by: EU JPND I BMBF, sb_search.searchresult.label.programSubmissionDate: 05/03/2024 https://www.gesundheitsindustrie-bw.de/en/database/funding/eu-joint-programme-neurodegenerative-disease-research-jpnd-mechanisms-and-measurement-disease-progression-early-phase-neurodegen
Neurodegenerative diseases - 12/12/2022 Blood-based biomarkers allow the early prediction of Alzheimer's risks Most dementia diseases develop insidiously and are only detected at an advanced stage. Researchers at the University of Heidelberg and the German Cancer Research Center (DKFZ) have now identified the glial fibre acidic protein (GFAP) in the blood as a promising biomarker that can be used to determine an increased risk of developing Alzheimer's disease up to 17 years before diagnosis.https://www.gesundheitsindustrie-bw.de/en/article/news/blood-based-biomarkers-allow-early-prediction-alzheimers-risks
Press release - 17/11/2022 New target for Alzheimer's therapies found DZNE researchers discover link between the protein medin and Alzheimer's disease. The protein medin is deposited in the blood vessels of the brains of Alzheimer's patients along with the protein amyloid-β. DZNE Researchers have discovered this so-called co-aggregation. They have now published their observation in the renowned journal Nature.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-target-alzheimers-therapies-found
Press release - 04/11/2022 How do our brain cells age? The health of nerve cells is closely linked to the auxiliary cells that surround them, the so-called glial cells. It still remains largely unknown what role glial cells play in age-related diseases.https://www.gesundheitsindustrie-bw.de/en/article/press-release/wie-altern-die-zellen-unserem-gehirn
Press release - 20/06/2022 Protein changes in the liquor indicate inflammatory processes in the brain Alzheimer's, Parkinson's and other neurodegenerative diseases are associated with inflammatory processes in the brain. German researchers have succeeded in identifying a group of proteins in the liquor that could provide information about such inflammatory processes. As so-called biomarkers, the proteins could help to better understand disease processes in the future and to test the effect of potential drugs against brain inflammation.https://www.gesundheitsindustrie-bw.de/en/article/press-release/protein-changes-liquor-indicate-inflammatory-processes-brain
Press release - 03/03/2022 Identifying Alzheimer's risks – as early as 17 years before diagnosis In order to develop approaches for the prevention and treatment of Alzheimer's dementia in clinical trials, it would be helpful to be able to identify people with a particularly high risk of developing the disease. But which biomarkers can indicate an increased likelihood of disease early on in symptom-free people who actually develop Alzheimer's later?https://www.gesundheitsindustrie-bw.de/en/article/press-release/identifying-alzheimers-risks-early-17-years-diagnosis
Press release - 25/11/2021 New Collaborative Research Centre at Ulm University Focusing on the factors that influence human aging After a highly competitive process Ulm University has been awarded its fifth Collaborative Research Centre (CRC). The new CRC 1506 ‘Aging at Interfaces’ addresses one of the most urgent medical challenges of our time: the aging of the human body and the diseases and constraints that are frequently associated with the aging process.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-collaborative-research-centre-ulm-university-focusing-factors-influence-human-aging
Press release - 10/06/2021 Nose2Brain – Active substances without detour through the nose into the brain Effective drugs for the treatment of diseases of the central nervous system do exist. However, the blood-brain barrier, which protects the brain as the body's control center, makes it especially difficult for therapeutic biomolecules to pass through. Thus, researchers from an international consortium coordinated by the Fraunhofer IGB have spent the last four and a half years developing a novel system in the EU project "N2B-patch"…https://www.gesundheitsindustrie-bw.de/en/article/press-release/nose2brain-active-substances-without-detour-through-nose-brain
Dossier - 10/11/2014 Cell and gene therapies from bench to bedside https://www.gesundheitsindustrie-bw.de/en/article/dossier/cell-and-gene-therapies-from-bench-to-bedside
Dossier - 15/10/2013 Adult stem cells hope for regenerative therapies Adult stem cells have the lifelong ability to generate new specialised cells. They secure the continuous replenishment of cells therefore enabling the constant replacement of dying cells with new ones. Progress in the characterisation isolation and specific differentiation of adult stem cells over recent years raises hopes for the future use of the cells in the therapy of degenerative diseases. Knowledge about adult stem cells also has the…https://www.gesundheitsindustrie-bw.de/en/article/dossier/adult-stem-cells-hope-for-regenerative-therapies